Renowned investment firm Renaissance Technologies, led by Jim Simons (Trades, Portfolio), has recently increased its stake in Corcept Therapeutics Inc (NASDAQ:CORT), a pharmaceutical company specializing in the treatment of severe metabolic, oncologic, and neuropsychiatric disorders. This transaction underscores the firm's confidence in Corcept Therapeutics, even as it navigates the volatile biotechnology sector.
On December 29, 2023, Renaissance Technologies, led by Jim Simons (Trades, Portfolio), expanded its investment portfolio by adding shares of Ennis Inc (NYSE:EBF). The transaction involved the acquisition of 12,000 shares at a trade price of $21.91. Following this addition, the firm now holds a total of 1,534,346 shares in Ennis Inc, which represents a 5.93% ownership stake in the company and a 0.06% position in the firm's portfolio.
On December 29, 2023, Renaissance Technologies, led by Jim Simons (Trades, Portfolio), made a notable addition to its investment portfolio by acquiring 2,669,209 shares of Smith & Wesson Brands Inc (NASDAQ:SWBI), a leading firearm manufacturer. Jim Simons (Trades, Portfolio), the founder of Renaissance Technologies Corporation, has been a prominent figure in the investment world since 1982.
On December 29, 2023, Jim Simons (Trades, Portfolio)'s firm Renaissance Technologies executed a notable transaction in the stock market, specifically targeting Vishay Precision Group Inc (NYSE:VPG). The firm reduced its holdings in VPG by 29,458 shares, which represented a -4.76% change in the investment. This adjustment in the portfolio of one of the world's most renowned quantitative investment firms has caught the attention of value investors seeking insights into market movements.
On December 29, 2023, Renaissance Technologies, led by Jim Simons (Trades, Portfolio), made a notable addition to its investment portfolio by acquiring 11,188 shares of Data I/O Corp (NASDAQ:DAIO). Despite the trade having a seemingly negligible impact on the overall portfolio, the move is significant given Simons's reputation for data-driven investment decisions.